On January 12, 2026, Zymeworks expanded its Board of Directors to nine members with the appointment of Brian Cherry, a private equity leader who has overseen buyout and growth investments totaling more than $25 billion in enterprise value. Mr. Cherry brings over 25 years of experience across healthcare, industrials, business services, financial services and consumer products. His previous roles include Managing Partner at Oak Hill Capital and board seats at more than a dozen public and private companies, the U.S. Air Force Academy Foundation and the University of Pennsylvania’s Undergraduate Financial Aid Leadership Council. This appointment caps a deliberate reduction of the board from twelve to nine directors over the past year, reflecting Zymeworks’ strategy to align board expertise with its evolving corporate strategy and to enhance oversight of capital allocation and strategic acquisitions.

Effective February 1, 2026, Dr. Sabeen Mekan will assume the role of Chief Medical Officer, overseeing clinical development, regulatory affairs, pharmacovigilance and clinical operations. Dr. Mekan succeeds Dr. Jeff Smith, who will retire on January 31, 2026, and then serve as an adviser during a transitional period. Concurrently, Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer, expanding his remit beyond technology and manufacturing operations to include quality and alliance management. In the first quarter of 2026, Leone Patterson (Chief Financial and Business Officer) and Daniel Dex (General Counsel) will depart, prompting a search for a permanent CFO; Kenneth Galbraith has been appointed Acting Chief Financial Officer until a successor is named.

Zymeworks has appointed five new Vice Presidents to strengthen key functional areas, demonstrating its commitment to leadership development. Laura O’Connor joins as Senior Vice President and Chief Human Resources Officer; Bijal Desai becomes Senior Vice President, Finance; Lindsey Foulkes is named Senior Vice President, Corporate Development and Strategy; Charles Chen takes on the role of Vice President, Translational Sciences; and Shrinal Inamdar assumes Vice President, Investor Relations. Additionally, Diana Papove was appointed Vice President, Corporate Communications, Victoria Spencer as Vice President, Treasury and Tax, and Lingxing Zheng as Vice President, Regulatory Affairs. These appointments align management resources with the company’s priorities of advancing its multifunctional biotherapeutics pipeline and optimizing its portfolio of licensed healthcare assets.